Published online Aug 10, 2016. doi: 10.5306/wjco.v7.i4.331
Peer-review started: April 23, 2016
First decision: June 6, 2016
Revised: July 12, 2016
Accepted: July 20, 2016
Article in press: July 22, 2016
Published online: August 10, 2016
Processing time: 99 Days and 19.2 Hours
AIM: To evaluate the current role of sorafenib, an oral multikinase inhibitor in the treatment of breast cancer.
METHODS: An extensive search of the literature until March 2016 was carried out in Medline and clinicaltrials.gov, by using the search terms “sorafenib” and “breast cancer”. Papers found were checked for further relevant publications. Overall, 21 relevant studies were found, 18 in advanced breast cancer (16 in stage IV and two in stages III-IV) and three in early breast cancer.
RESULTS: Among studies in advanced breast cancer, there were two trials with sorafenib as monotherapy, four trials of sorafenib in combination with taxanes, two in combination with capecitabine, one with gemcitabine and/or capecitabine, one with vinorelbine, one with bevacizumab, one with pemetrexed and one with ixabepilone, three trials of sorafenib in combination with endocrine therapy and two trials in women with brain metastases undergoing whole brain radiotherapy. In addition, there was one trial of sorafenib added to standard chemotherapy in the adjuvant setting, and two trials in the neoadjuvant setting. In general, sorafenib was well tolerated in breast cancer patients, though its dosage had to be adjusted in some trials, and discontinuation rates were high, particularly for the combination of sorafenib with anastrozole. Sorafenib monotherapy and combinations with taxanes, bevacizumab and ixabepilone showed inadequate efficacy, while efficacy results from combinations with gemcitabine and/or capecitabine and possibly tamoxifen were more promising.
CONCLUSION: At present, sorafenib should not be used for the treatment of breast cancer outside of clinical trials and more clinical data are needed in order to support its standard use in breast cancer therapy.
Core tip: In this systematic review of the literature, the role of sorafenib in the treatment of breast cancer has been evaluated. Regarding toxicity, sorafenib was generally well tolerated in breast cancer patients, while in terms of efficacy the most promising results came from clinical trials evaluating sorafenib in combination with gemcitabine and/or capecitabine and possibly tamoxifen. Efficacy was inadequate with sorafenib monotherapy and combinations with taxanes, bevacizumab and ixabepilone.
- Citation: Zafrakas M, Papasozomenou P, Emmanouilides C. Sorafenib in breast cancer treatment: A systematic review and overview of clinical trials. World J Clin Oncol 2016; 7(4): 331-336
- URL: https://www.wjgnet.com/2218-4333/full/v7/i4/331.htm
- DOI: https://dx.doi.org/10.5306/wjco.v7.i4.331
Breast cancer is the most frequently diagnosed malignancy and the leading cause of cancer death among women worldwide. It is estimated that each year breast cancer will be diagnosed in 1.7 million women and cause 520000 deaths around the world. Furthermore, it is estimated that breast cancer alone accounts for 25% of all cancer cases and 15% of all cancer deaths among females[1]. Despite the widespread use of breast cancer screening, leading to detection at early stages[2] and despite ongoing progress in adjuvant treatment strategies[3], still many women will develop metastatic disease and eventually die from breast cancer. Hence, new treatment modalities are needed, especially in order to treat breast cancer metastases.
Sorafenib (Nexavar®, Bayer and Onyx Pharmaceuticals) is a small molecule, which acts as an inhibitor of various tyrosine kinases, including BRAF, C-RAF, vascular endothelial growth factor receptor and platelet-derived growth factor receptor, RET, c-KIT and FMS-like tyrosine kinase-3[4-6]. Sorafenib is administered orally, and it is approved for the treatment of advanced renal cell carcinoma, advanced hepatocellular carcinoma, and advanced thyroid cancer[6-8]. Its possible mechanisms of anti-tumor action include inhibition of tumor growth and tumor progression, inhibition of metastasis and angiogenesis, as well as down-regulation of mechanisms that protect tumors from apoptosis[6-8]. The clinical application of sorafenib, especially in the treatment of renal cancer, is based on its activity on angiogenesis inhibition, and parallels other anti-angiogenetic agents[9]. Since targeting angiogenesis has been also a valid approach in the treatment of advanced breast cancer, the role of sorafenib, was investigated for this indication as well[10]. The aim of the present study was to evaluate the current role of sorafenib in the treatment of breast cancer, especially its efficacy and safety profile, based on available evidence from clinical trials.
An extensive search of the literature was carried out in the bibliographic database Medline for articles ever published until March 2016, by using the search terms “sorafenib” and “breast cancer” in the field “Title”. No other limits or filters were used, including no limits for language and year of publication. A further search was conducted in clinicaltrials.gov, a public database of registered clinical trials, by using the same key-words, i.e., “sorafenib” and “breast cancer”.
Inclusion criteria included published and ongoing clinical trials evaluating the efficacy and toxicity of sorafenib in early and advanced breast cancer. Exclusion criteria included the following study characteristics: Case reports, animal and in vitro studies, clinical trials with inconclusive information and clinical trials in various cancer types besides breast cancer.
At first, the titles of studies were screened and irrelevant publications were excluded. Evaluation of the abstract of the remaining studies followed. Finally, the content of the main text of identified studies was evaluated. The lists of references of relevant studies, including relevant review articles[11-13], were searched in order to identify possibly additional articles meeting the inclusion criteria. A meta-analysis was not possible due to extensive differences between studies.
Thirty-six papers were found by the Medline search and 30 clinical trials by the clinicaltrials.gov search. After screening the titles, abstracts and/or the full-texts of these studies, 21 relevant trials were identified; most of these studies involved patients with metastatic (16 studies) and/or advanced breast cancer (stages III-IV; two studies), while three studies involved patients with breast cancer stages I-III. An overview of these clinical trials is presented in Table 1.
| Ref. | Regimen | Study design | Number of patients | Disease stage | Toxicity | Clinical efficacy |
| Moreno-Aspitia et al[14] | Sorafenib as monotherapy | Phase II; 1 arm | 23 | Stage IV | Manageable | Low |
| Bianchi et al[15] | Sorafenib as monotherapy | Phase II; 1 arm | 54 | Stage IV | Manageable | Low |
| Gradishar et al[16] | Sorafenib + paclitaxel | RCT (vs placebo) | 237 | Stage IV | Manageable | Better TTP |
| NCT00622466 (ongoing)[17] | Sorafenib + paclitaxel | RCT (vs placebo) | 41 | Stage IV | NA | NA |
| NCT00499525 (ongoing)[17] | Sorafenib + paclitaxel | RCT (vs placebo) | 180 | Stages III-IV | NA | NA |
| Mariani et al[18] | Sorafenib + docetaxel and/or letrozole | RCT (vs placebo) | 218 | Stage IV | Manageable | Not better |
| Baselga et al[19] | Sorafenib + capecitabine | RCT (vs placebo) | 229 | Stage IV | High | Better PFS |
| Baselga et al[20] (ongoing) | Sorafenib + capecitabine | RCT (vs placebo) | 519 | Stage IV | NA | NA |
| Schwartzberg et al[21] | Sorafenib + gemcitabine and/or capecitabine | RCT (vs placebo) | 160 | Stages III-IV | Manageable | Better PFS |
| Luu et al[22] | Sorafenib + vinorelbine | Phase I/II; 1 arm | 11/35 | Stage IV | Manageable | Low |
| Mina et al[23] | Sorafenib + bevacizumab | Phase II; 1 arm | 18 | Stage IV | Substantial | Low |
| NCT02624700 (ongoing)[17] | Sorafenib + pemetrexed | Phase II; 1 arm | 35 | Stage IV | NA | NA |
| Yardley et al[24] | Sorafenib + ixabepilone | Phase I/II; 1 arm | 10/76 | Stage IV | High | Low |
| Isaacs et al[25] | Sorafenib + anastrozole | Phase I/II; 1 arm | 35 | Stage IV | High | Benefit 23% |
| Massarweh et al[26] | Sorafenib + endocrine therapy1 | Phase II; 1 arm | 11 | Stage IV | Manageable | Promising4 |
| NCT00634634 (ongoing)[17] | Sorafenib + letrozole | Phase I/II; 1 arm | 54 | Stage IV | NA | NA |
| NCT01724606 (ongoing)[17] | Sorafenib + WBRT | Phase I | 24 | Stage IV | NA | NA |
| NCT01621906 (ongoing)[17] | Sorafenib + WBRT (18F-FLT-PET vs MRI) | Diagnostic | 20 | Stage IV | NA | NA |
| Spigel et al[27] | Sorafenib + AC-T2 | One arm | 45 | Stages I-III | Limited | NA |
| Loibl et al[28] | Sorafenib + EC-T3 | Phase II | 36 | Stages II-III | Manageable | pCR 27.7% |
| Bazzola et al[29] | Sorafenib + letrozole + cyclophosphamide3 | One arm | 13 | Stages II-III | Tolerable | Clinical /no pCR |
Among studies in metastatic and/or advanced breast cancer, there were two trials with sorafenib as monotherapy[13-15], three trials of sorafenib in combination with paclitaxel[16,17], one trial of sorafenib in combination with docetaxel and/or letrozole[18], two trials of sorafenib in combination with capecitabine[19,20] and one with gemcitabine and/or capecitabine[21]. In stage IV disease there was also one trial of sorafenib in combination with vinorelbine[22], one with bevacizumab[23], one with pemetrexed[17] and one with ixabepilone[24].
Regarding endocrine therapy in metastatic breast cancer, there were three trials evaluating sorafenib in combination with endocrine therapy: One in combination with anastrozole[25], one in combination with tamoxifen or anastrozole or letrozole or exemestane or fluvestrant[26] and one in combination with letrozole[17]. Finally, two trials were found, involving patients with brain metastases undergoing whole brain radiotherapy[17].
In breast cancer stages I-III, there was one trial of sorafenib added to standard AC-T chemotherapy in the adjuvant setting[27], and two trials in the neoadjuvant setting in stages II-III, one in combination with standard EC-T chemotherapy[28] and one in combination with letrozole and cyclophosphamide[29].
Sorafenib, a multiple tyrosine kinase inhibitor, is an orally administered small molecule, which has been evaluated in numerous clinical trials in breast cancer patients. The present study aimed to clarify the current role of sorafenib in breast cancer treatment.
Most clinical trials identified in our study involved patients with advanced and/or metastatic breast cancer. Sorafenib as a single agent was administered in two phase II clinical trials involving 23[14] and 54 patients[15] with stage IV breast cancer; in both studies, toxicity was clinically manageable, whereas efficacy was limited, precluding future application of sorafenib monotherapy in breast cancer.
In a multi-national, randomized, placebo-controlled trial, involving 237 patients with metastatic breast cancer, sorafenib was added to paclitaxel[16]; toxicity was manageable with dose reduction; time to progression and overall response were significantly improved; however progression-free survival and overall survival did not differ significantly. Results from two ongoing randomized, placebo-controlled trials (NCT00622466 and NCT00499525[17]) evaluating the same combination are awaited. In another randomized, placebo-controlled trial, published only in abstract form, involving 218 patients with metastatic breast cancer, sorafenib was added to docetaxel and/or letrozole[18]; though toxicity was manageable, no improvement in terms of efficacy was found.
Baselga et al[19] reported the results of a phase IIB trial, involving 229 patients with HER-2-negative metastatic breast cancer; patients were randomly assigned to first- or second-line capecitabine in combination with sorafenib or placebo; though the addition of sorafenib to capecitabine significantly improved progression free survival, there was no significant improvement for overall survival and overall response, and the dose of sorafenib (400 mg twice daily) resulted in unacceptable toxicity for many patients. These findings led to the initiation of RESILIENCE[20], an ongoing multi-national, randomized, placebo-controlled, phase III confirmatory trial in HER-2-negative, stage IV, breast cancer patients, comparing capecitabine plus a reduced initial sorafenib dose and possible dose-escalation with capecitabine plus placebo; enrollment began in November 2010 with a target of approximately 519 patients. In a similar study, published by Schwartzberg et al[21], 160 HER-2-negative patients with locally advanced or metastatic breast cancer whose disease progressed during or after bevacizumab were randomized to chemotherapy plus sorafenib or chemotherapy plus placebo; initially, chemotherapy was gemcitabine, but later, capecitabine was allowed as an alternative; the addition of sorafenib provided a statistically significant progression-free survival benefit, with manageable toxicities but frequent dose reductions.
Combinations of sorafenib with other agents in metastatic breast cancer have shown less promising results. In particular, the combination of sorafenib with vinorelbine in a phase I and II study with 11 and 35 patients with metastatic breast cancer, respectively, showed manageable toxicity but low efficacy; the authors concluded that this combination may be of interest if specific biomarkers guiding patient selection can be identified[22]. The combination of sorafenib with bevacizumab in a phase II, one arm study, involving 18 patients had substantial toxicity and minimal efficacy[23]. Likewise, in a Phase I and II study with 10 and 76 patients with metastatic breast cancer, respectively, the combination of ixabepilone and sorafenib was poorly tolerated and the activity of the combination was similar to the activity previously reported with single-agent ixabepilone or taxanes[24]. Results from an ongoing study (NCT02624700)[17] in stage IV breast cancer evaluating the combination of sorafenib with pemetrexed are awaited.
Regarding sorafenib in combination with endocrine therapy in hormone receptor positive metastatic breast cancer, results from two trials have been reported[25,26]. In a phase I/II trial, involving 35 patients who had disease recurrence or progression while on aromatase inhibitors, the combination of sorafenib with anastrozole was associated with an encouraging clinical benefit rate of 23%, suggesting that sorafenib may be able to restore sensitivity to hormone therapy; however, this combination was associated with significant toxicity[25]. In a pilot phase II study, involving 11 patients, sorafenib was added to endocrine therapy, to tamoxifen in 7 cases, and in one case each to anastrozole, letrozole, exemestane and fulvestrant; toxicity was manageable with promising results in terms of efficacy, since most patients developed stable disease[26]. Results from an ongoing study (NCT00634634) evaluating the combination of sorafenib with letrozole are awaited[17].
A special issue in metastatic breast cancer is the administration of sorafenib to patients with brain metastases, undergoing whole brain radiotherapy (WBRT). In an ongoing phase I clinical trial (NCT01724606)[17], the safety and efficacy of this combination is under evaluation. Another ongoing study (NCT01621906)[17] from the same center compares 18F-FLT-PET with MRI as imaging methods in the evaluation of response to treatment with sorafenib and WBRT.
Finally, the addition of sorafenib to chemotherapy in the adjuvant and neoadjuvant setting has been evaluated in three clinical trials[27-29]. In a pilot, one arm study[27], 45 patients with node-positive or high-risk early-stage breast cancer (stages I-III) received adjuvant doxorubicin and cyclophosphamide followed by paclitaxel and sorafenib; though sorafenib was generally associated with limited severe toxicity, many patients discontinued sorafenib early; the authors concluded that additional studies of sorafenib in breast cancer in the neoadjuvant and triple-negative settings are warranted. In SOFIA[28], a phase II, single arm clinical trial, 36 HER-2-negative patients with stage II-III disease received neoadjuvant EC (epirubicin plus cyclophosphamide) in 3-weekly cycles followed or preceded by 12 wk of paclitaxel; sorafenib was added to EC or paclitaxel or the whole chemotherapy regimen; the authors concluded that the addition of sorafenib to this regimen is feasible if the starting dose is 200 mg, escalated every 3 wk based on patients’ individual toxicities. In another single-arm study in the neoadjuvant setting[29], 13 estrogen receptor-positive, postmenopausal, breast cancer patients with stage II-III disease received for 6 mo the combination of letrozole, metronomic cyclophosphamide and sorafenib; the combination was well tolerated, and although no pathological complete response was found, still clinical response rates were promising.
In conclusion, sorafenib is generally well tolerated in breast cancer patients with either metastatic disease or at earlier stages. However, in some clinical trials sorafenib discontinuation rates were high or sorafenib dosage had to be adjusted, due to unacceptable toxicity. To date, sorafenib as a single agent and combinations of sorafenib with taxanes, bevacizumab and ixabepilone have shown inadequate efficacy. More promising efficacy results came from clinical trials with sorafenib in combination with gemcitabine and/or capecitabine and possibly tamoxifen. At present, sorafenib should not be routinely administered for the treatment of breast cancer outside of clinical trials. More evidence from ongoing and future clinical trials should clarify the possible role of sorafenib in the treatment of breast cancer patients.
Sorafenib is a small molecule, acting as an inhibitor of various tyrosine kinases; it is approved for the treatment of advanced renal cell carcinoma, advanced hepatocellular carcinoma, and advanced thyroid cancer. Its possible mechanisms of action include inhibition of tumor growth, progression, metastasis and angiogenesis and down-regulation of mechanisms protecting tumors from apoptosis. The clinical application of sorafenib, especially in renal cancer, is based on its anti-angiogenesis activity. Since targeting angiogenesis has been also a valid approach in the treatment of advanced breast cancer, the role of sorafenib, was investigated for this indication as well. The aim of the present study was to evaluate the current role of sorafenib in the treatment of breast cancer, based on available evidence from clinical trials.
Sorafenib is being evaluated in combination with various chemotherapeutic and/or endocrine agents, especially in the treatment of advanced breast cancer. The current hotspot of research is the clinical application of sorafenib in breast cancer therapy in combination with various agents, in order to improve treatment efficacy with an acceptable toxicity profile.
In this systematic review of the literature, the role of sorafenib in the treatment of breast cancer was evaluated. Overall, 21 relevant studies were identified, 18 in advanced breast cancer (16 in stage IV and two in stages III-IV) and three in early breast cancer. In advanced breast cancer, there were two trials with sorafenib as monotherapy, four trials of sorafenib in combination with taxanes, two with capecitabine, one with gemcitabine and/or capecitabine, one with vinorelbine, one with bevacizumab, one with pemetrexed, one with ixabepilone, three trials with endocrine therapy and two trials in women with brain metastases undergoing whole brain radiotherapy. In early breast cancer, there was one trial of sorafenib added to standard chemotherapy in the adjuvant setting, and two trials in the neoadjuvant setting. In terms of efficacy, sorafenib monotherapy and combinations with taxanes, bevacizumab and ixabepilone showed inadequate efficacy, while results from combinations with gemcitabine and/or capecitabine and possibly tamoxifen were more promising. In terms of toxicity, sorafenib was well tolerated in breast cancer patients, though its dosage had to be adjusted in some trials, and discontinuation rates were high, particularly for the combination of sorafenib with anastrozole.
At present, sorafenib should not be used for the treatment of breast cancer outside of clinical trials; more clinical data are needed in order to support its standard use in breast cancer therapy.
Sorafenib (Nexavar®, Bayer and Onyx Pharmaceuticals): A small molecule, administered orally. Sorafenib is approved for the treatment of the following types of cancer: Advanced renal cell carcinoma, advanced hepatocellular carcinoma, and advanced thyroid cancer. Sorafenib chemical mechanism of action: Inhibition of various tyrosine kinases, including BRAF, C-RAF, vascular endothelial growth factor receptor and platelet-derived growth factor receptor, RET, c-KIT and FMS-like tyrosine kinase-3. Sorafenib biological mechanism of action: Inhibition of tumor growth, progression, metastasis and angiogenesis and down-regulation of mechanisms protecting tumors from apoptosis. Rationale for clinical application of sorafenib: Mainly its activity on angiogenesis inhibition, especially in advanced renal cancer. Tumor angiogenesis: Formation of new blood vessels by malignant tumors.
This is an excellent and well designed article.
Manuscript Source: Invited manuscript
Specialty Type: Oncology
Country of Origin: Greece
Peer-Review Report Classification
Grade A (Excellent): A
Grade B (Very good): B, B, B
Grade C (Good): 0
Grade D (Fair): D
Grade E (Poor): 0
P- Reviewer: Cosmi E, Khajehei M, Sonoda K, Tsikouras PPT, Yokoyama Y S- Editor: Gong XM L- Editor: A E- Editor: Lu YJ
| 1. | Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87-108. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 18694] [Cited by in F6Publishing: 21122] [Article Influence: 2346.9] [Reference Citation Analysis (2)] |
| 2. | Oeffinger KC, Fontham ET, Etzioni R, Herzig A, Michaelson JS, Shih YC, Walter LC, Church TR, Flowers CR, LaMonte SJ. Breast Cancer Screening for Women at Average Risk: 2015 Guideline Update From the American Cancer Society. JAMA. 2015;314:1599-1614. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 1105] [Cited by in F6Publishing: 1090] [Article Influence: 121.1] [Reference Citation Analysis (0)] |
| 3. | Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M, Thürlimann B, Senn HJ; Panel Members. Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol. 2015;26:1533-1546. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 1278] [Cited by in F6Publishing: 1254] [Article Influence: 139.3] [Reference Citation Analysis (0)] |
| 4. | Adnane L, Trail PA, Taylor I, Wilhelm SM. Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol. 2006;407:597-612. [PubMed] [Cited in This Article: ] |
| 5. | Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64:7099-7109. [PubMed] [Cited in This Article: ] |
| 6. | Pitoia F, Jerkovich F. Selective use of sorafenib in the treatment of thyroid cancer. Drug Des Devel Ther. 2016;10:1119-1131. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 49] [Cited by in F6Publishing: 48] [Article Influence: 6.0] [Reference Citation Analysis (0)] |
| 7. | Gao JJ, Shi ZY, Xia JF, Inagaki Y, Tang W. Sorafenib-based combined molecule targeting in treatment of hepatocellular carcinoma. World J Gastroenterol. 2015;21:12059-12070. [PubMed] [DOI] [Cited in This Article: ] [Cited by in CrossRef: 44] [Cited by in F6Publishing: 50] [Article Influence: 5.6] [Reference Citation Analysis (0)] |
| 8. | Fishman MN, Tomshine J, Fulp WJ, Foreman PK. A systematic review of the efficacy and safety experience reported for sorafenib in advanced renal cell carcinoma (RCC) in the post-approval setting. PLoS One. 2015;10:e0120877. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis (0)] |
| 9. | Domblides C, Gross-Goupil M, Quivy A, Ravaud A. Emerging antiangiogenics for renal cancer. Expert Opin Emerg Drugs. 2013;18:495-511. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis (0)] |
| 10. | Sledge GW, Rugo HS, Burstein HJ. The role of angiogenesis inhibition in the treatment of breast cancer. Clin Adv Hematol Oncol. 2006;4:1-10; quiz 11-12. [PubMed] [Cited in This Article: ] |
| 11. | Tan QX, Qin QH, Lian B, Yang WP, Wei CY. Sorafenib-based therapy in HER2-negative advanced breast cancer: Results from a retrospective pooled analysis of randomized controlled trials. Exp Ther Med. 2014;7:1420-1426. [PubMed] [Cited in This Article: ] |
| 12. | Chen J, Tian CX, Yu M, Lv Q, Cheng NS, Wang Z, Wu X. Efficacy and Safety Profile of Combining Sorafenib with Chemotherapy in Patients with HER2-Negative Advanced Breast Cancer: A Meta-analysis. J Breast Cancer. 2014;17:61-68. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis (0)] |
| 13. | Moreno-Aspitia A. Clinical overview of sorafenib in breast cancer. Future Oncol. 2010;6:655-663. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.4] [Reference Citation Analysis (0)] |
| 14. | Moreno-Aspitia A, Morton RF, Hillman DW, Lingle WL, Rowland KM, Wiesenfeld M, Flynn PJ, Fitch TR, Perez EA. Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336. J Clin Oncol. 2009;27:11-15. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 122] [Cited by in F6Publishing: 125] [Article Influence: 8.3] [Reference Citation Analysis (0)] |
| 15. | Bianchi G, Loibl S, Zamagni C, Salvagni S, Raab G, Siena S, Laferriere N, Peña C, Lathia C, Bergamini L. Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer. Anticancer Drugs. 2009;20:616-624. [PubMed] [Cited in This Article: ] |
| 16. | Gradishar WJ, Kaklamani V, Sahoo TP, Lokanatha D, Raina V, Bondarde S, Jain M, Ro SK, Lokker NA, Schwartzberg L. A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer. Eur J Cancer. 2013;49:312-322. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 65] [Cited by in F6Publishing: 70] [Article Influence: 5.8] [Reference Citation Analysis (0)] |
| 17. | ClinicalTrials. gov. Studies found for: “Sorafenib” AND “Breast Cancer”. [accessed 2016; Mar 27] Available from: https://clinicaltrials.gov/ct2/results?term=”Sorafenib” AND “Breast Cancer”&Search=Search. [Cited in This Article: ] |
| 18. | Mariani G, Burdaeva O, Roman L, Staroslawska E, Udovitsa D, Driol P, Goisis G, Zamagni C, Semiglazov V, Gianni L. A Double-blind, Randomized Phase lib Study Evaluating the Efficacy and Safety of Sorafenib (SOR) Compared to Placebo (PL) When Administered in Combination with Docetaxel And/or Letrozole in Patients with Metastatic Breast Cancer (MBC): FM-B07-01 Trial (Abstract). Eur J Cancer. 2011;47:10. [Cited in This Article: ] |
| 19. | Baselga J, Segalla JG, Roché H, Del Giglio A, Pinczowski H, Ciruelos EM, Filho SC, Gómez P, Van Eyll B, Bermejo B. Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer. J Clin Oncol. 2012;30:1484-1491. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 132] [Cited by in F6Publishing: 134] [Article Influence: 11.2] [Reference Citation Analysis (0)] |
| 20. | Baselga J, Costa F, Gomez H, Hudis CA, Rapoport B, Roche H, Schwartzberg LS, Petrenciuc O, Shan M, Gradishar WJ. A phase 3 tRial comparing capecitabinE in combination with SorafenIb or pLacebo for treatment of locally advanced or metastatIc HER2-Negative breast CancEr (the RESILIENCE study): study protocol for a randomized controlled trial. Trials. 2013;14:228. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 2.6] [Reference Citation Analysis (0)] |
| 21. | Schwartzberg LS, Tauer KW, Hermann RC, Makari-Judson G, Isaacs C, Beck JT, Kaklamani V, Stepanski EJ, Rugo HS, Wang W. Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab. Clin Cancer Res. 2013;19:2745-2754. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 53] [Cited by in F6Publishing: 57] [Article Influence: 5.2] [Reference Citation Analysis (0)] |
| 22. | Luu T, Frankel P, Chung C, Chow W, Mortimer J, Hurria A, Somlo G. Phase I/II trial of vinorelbine and sorafenib in metastatic breast cancer. Clin Breast Cancer. 2014;14:94-100. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis (0)] |
| 23. | Mina LA, Yu M, Johnson C, Burkhardt C, Miller KD, Zon R. A phase II study of combined VEGF inhibitor (bevacizumab+sorafenib) in patients with metastatic breast cancer: Hoosier Oncology Group Study BRE06-109. Invest New Drugs. 2013;31:1307-1310. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis (0)] |
| 24. | Yardley DA, Dickson N, Drosick D, Earwood C, Inhorn R, Murphy P, Hainsworth JD. Sorafenib Plus Ixabepilone as First-Line Treatment of Metastatic HER2-Negative Breast Cancer: A Sarah Cannon Research Institute Phase I/II Trial. Clin Breast Cancer. 2016;16:180-187. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis (0)] |
| 25. | Isaacs C, Herbolsheimer P, Liu MC, Wilkinson M, Ottaviano Y, Chung GG, Warren R, Eng-Wong J, Cohen P, Smith KL. Phase I/II study of sorafenib with anastrozole in patients with hormone receptor positive aromatase inhibitor resistant metastatic breast cancer. Breast Cancer Res Treat. 2011;125:137-143. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 1.8] [Reference Citation Analysis (0)] |
| 26. | Massarweh S, Moss J, Wang C, Romond E, Slone S, Weiss H, Karabakhtsian RG, Napier D, Black EP. Impact of adding the multikinase inhibitor sorafenib to endocrine therapy in metastatic estrogen receptor-positive breast cancer. Future Oncol. 2014;10:2435-2448. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis (0)] |
| 27. | Spigel DR, Hainsworth JD, Burris HA, Molthrop DC, Peacock N, Kommor M, Vazquez ER, Greco FA, Yardley DA. A pilot study of adjuvant doxorubicin and cyclophosphamide followed by paclitaxel and sorafenib in women with node-positive or high-risk early-stage breast cancer. Clin Adv Hematol Oncol. 2011;9:280-286. [PubMed] [Cited in This Article: ] |
| 28. | Loibl S, Rokitta D, Conrad B, Harbeck N, Wüllner M, Warm M, Schwedler K, Gerber B, Schrader I, Eidtmann H. Sorafenib in the Treatment of Early Breast Cancer: Results of the Neoadjuvant Phase II Study - SOFIA. Breast Care (Basel). 2014;9:169-174. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis (0)] |
| 29. | Bazzola L, Foroni C, Andreis D, Zanoni V, R Cappelletti M, Allevi G, Aguggini S, Strina C, Milani M, Venturini S. Combination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancer. Br J Cancer. 2015;112:52-60. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.0] [Reference Citation Analysis (0)] |